Ribociclib: new antitumor drug of cyclindependent kinase 4/6 inhibitor / 药物评价研究
mei Yan WANG; Chunmiao XUE; wei Xiao YU; ling Jun CAO.
Drug Evaluation Research
; (6): 1520-1524, 2017.
Artículo
en Zh
| WPRIM | ID: wpr-663255
Ribociclib is an oral small molecule cyclindependent kinase 4/6 inhibitor,which inhibits tumor progression by inhibiting the conversion of tumor cells from G1 phase to S phase.The combination ofribociclib and letrozole was approved in the United States on March 13,2017 as a treatment for HR+/HER2-advanced and metastatic breast cancer patients.Clinical results showed that the drug on advanced and metastatic tumors had a significant inhibitory effect and could extend the survival of patients without deterioration compared with using letrozole alone.The incidence of adverse drug reactions is higher,but the tolerance is better.This article focuses on pharmacodynamics,pharmacokinetic,clinical results and adverse effects of this drug.
Biblioteca responsable:
WPRO
Texto completo
Documentos relacionados